Email updates

Keep up to date with the latest news and content from BMC Neurology and BioMed Central.

Open Access Case report

Stroke in hereditary hemorrhagic telangiectasia patients. New evidence for repeated screening and early treatment of pulmonary vascular malformations: two case reports

Espartaco Ribeiro1*, Julien Cogez1, Emmanuel Babin2, Fausto Viader1 and Gilles Defer1

Author Affiliations

1 Service de Neurologie, Centre Hospitalier Universitaire Côte de Nacre, 14033 cedex 9, Caen, France

2 Service d'Oto-Rhino-Laryngologie, Centre Hospitalier Universitaire, Caen, France

For all author emails, please log on.

BMC Neurology 2011, 11:84  doi:10.1186/1471-2377-11-84


The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1471-2377/11/84


Received:21 March 2011
Accepted:9 July 2011
Published:9 July 2011

© 2011 Ribeiro et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Paradoxical embolism due to pulmonary arteriovenous malformations is the main mechanism of brain infarction in patients with hereditary hemorrhagic telangiectasia. International Guidelines have recently been published to clarify the performance of screening tests and the effectiveness of treatment for pulmonary arteriovenous malformations.

Case Presentation

We present two cases of hereditary hemorrhagic telangiectasia patients of our hospital who experienced an acute stroke secondary to paradoxical embolism.

Conclusions

These two cases show that the guidelines must be followed to prevent the occurrence of ischemic stroke in patients with hereditary hemorrhagic telangiectasia, and that although they may be adequate in most cases, there are some patients who need a more personalized approach.

Background

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease with variable penetrance and an estimated prevalence of 1/5000 [1]. Strokes are a major complication, occurring in 10 to 19% of HHT patients [2]. Paradoxical embolism due to pulmonary arteriovenous malformations (PAVMs), which are present in approximately 15-50% of patients with HHT, is the main mechanism of brain infarction [3]. Embolization of PAVMs has proven to be a safe and effective treatment in this situation [4]. We present two cases of acute ischemic stroke secondary to paradoxical embolism in HHT patients in order to discuss the performance of screening tests and the effectiveness of treatment for PAVMs published in the HHT International Guidelines in 2009 [5].

Case Presentations

Patient 1: a 35-year-old man with a SMAD4 mutation

In February of 2003, an abnormality was detected on a chest x-ray by an occupational physician. A thoracic CT scan showed asymptomatic PAVMs with a feeding artery diameter (FAD) of 2.4 mm (Figure 1A). One month later, the patient had sudden-onset weakness in the right hand and Wernicke aphasia which spontaneously resolved in 1 hour. The diffusion-weighted MRI showed a left temporal infarct (Figure 1B), and right apex lobe PAVMs were confirmed by pulmonary angiography. Thrombophilia work-up and venous ultrasonography were normal. Other etiologic investigations were negative and the stroke was attributed to paradoxical embolisms. Embolization of the PAVMs was successfully performed (Figure 1C) and antiplatelet therapy was started. No stroke recurrence or complications were observed during 7 years of follow-up.

thumbnailFigure 1. Radiological features of patient 1. A: Contrast-enhanced thoracic CT scan shows PAVMs (arrow); B: Brain MRI diffusion hyperintensity in the left temporal cortical region; C: Pulmonary angiography showing PAVMs after embolization (arrow).

Patient 2: a 36-year-old woman with an ENG mutation

This patient was diagnosed with HHT in 1995 and was regularly followed-up in the Otorhinolaryngology and Pneumology departments. In 2005, she complained of dyspnea and repeated hemoptysis that led to the discovery of a PAVM in the right pulmonary lobe, which was treated by coil embolization. In October 2009, the patient experienced gait disturbance and weakness of the right arm which lasted for 60 minutes. The clinical examination revealed a skew deviation of gaze that disappeared in 48 hours. The transthoracic contrast echocardiography showed an extracardiac shunt and the venous ultrasonography revealed a bilateral deep venous thrombosis (DVT) in both legs. The diffusion-weighted MRI showed right midbrain and anterior-medial thalamic infarctions (Figure 2A). New PAVMs were found in the right lower lobe using a thoracic CT scan (Figure 2B). Other investigations were negative. A paradoxical embolism from the DVT was thought to be the cause of stroke. A coil embolization was successfully performed (Figure 2C) and treatment with warfarin started. No recurrence or complication has been observed in the following 2 years.

thumbnailFigure 2. Radiological features of patient 2. A: Brain MRI diffusion hyperintensity in the right anterior-medial thalamus region; B: Contrast-enhanced thoracic CT scan shows PAVMs (arrow); C: Pulmonary angiography shows second PAVMs embolized (arrow).

Conclusion

International Guidelines were published in 2009 to clarify the performance of screening tests and the effectiveness of treatment for PAVMs. The selection of PAVMs for embolization is based on feeding artery diameter, generally 3 mm or greater, though targeting PAVMs with a feeding artery diameter as low as 2 mm may be appropriate [5]. Asymptomatic PAVMs were discovered in the first patient with an FAD less than 3 mm. He was not treated in agreement with the international recommendations. Unfortunately a stroke occurred one month later and embolization was finally performed. This confirms that a paradoxical embolism may occur when the FAD is less than 3 mm and embolization of PAVMs should always be discussed.

For patients who have PAVMs, the expert panel recommends that clinicians provide long-term follow-up, consisting of a first screening 6 to 12 months after treatment, then screenings approximately every 3 years after embolization with a multidetector thoracic CT scan, in order to detect growth of untreated PAVMs as well as reperfusion of treated PAVMs. A first screening 6 to 12 months after treatment then approximately every 3 years after embolization with a multidetector thoracic CT scan [5]. The second patient had a past medical history of PAVMs embolized in May 2005. Regular follow-ups with respiratory functional explorations and pulmonary x-rays were performed, but they could not prevent the occurrence of stroke. This case confirms the importance of monitoring patients using the multidetector thoracic CT with thin-cut (eg.1-2 mm) reconstructions and not with other methods that appear less efficient.

Therefore, this work show first, the necessity of closely monitoring patients with HHT in accordance with the international guidelines, and second, that treatment of PAVMs with transcatheter embolotherapy should be discussed on a case by case basis no matter the size of the FAD.

Consent

Written informed consent was obtained from the patients for publication of these cases reports and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

List of abbreviations

PAVMs: Pulmonary arteriovenous malformations; HHT: Hereditary hemorrhagic telangiectasia; MRI: Magnetic resonance imaging; DVT: Deep venous thrombosis; FAD: Feeding artery diameter; CT: Computed tomography.

Conflict of Interest/Disclosure

The authors declare that they have no competing interests.

Authors' contributions

ER was responsible for overall study design, management, analysis, and writing. JC was equally responsible for the design, management, and analysis in the study. EB, FV, and GD provided technical oversight to the study, which included reviewing writing parts of the manuscript.

All authors read and approved the final manuscript

Acknowledgements

We thank Meggie Chochol for editing the manuscript.

References

  1. Kjeldsen AD, Vase P, Green A: Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients.

    J Intern Med 1999, 245:31-39. PubMed Abstract | Publisher Full Text OpenURL

  2. Cottin V, Dupuis-Girod S, Lesca G, Cordier JF: Pulmonary Vascular Manifestations of Hereditary Hemorrhagic Telangiectasia (Rendu-Osler Disease).

    Respiration 2007, 74:361-378. PubMed Abstract | Publisher Full Text OpenURL

  3. Cottin V, Plauchu H, Bayle JY, Barthelet M, Revel D, Cordier JF: Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia.

    Am J Respir Crit Care Med 2004, 169:994-1000. PubMed Abstract | Publisher Full Text OpenURL

  4. Mager JJ, Overtoom TT, Blauw H, Lammers JW, Westermann CJ: Embolotherapy of pulmonary arteriovenous malformations: long-term results in 112 patients.

    J Vasc Interv Radiol 2004, 15:451-456. PubMed Abstract OpenURL

  5. Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, Spears J, Brown DH, Buscarini E, Chesnutt MS, Cottin V, Ganguly A, Gossage JR, Guttmacher AE, Hyland RH, Kennedy SJ, Korzenik J, Mager JJ, Ozanne AP, Piccirillo JF, Picus D, Plauchu H, Porteous MEM, Pyeritz RE, Ross DA, Sabba C, Swanson K, Terry P, Wallace MC, Westermann CJJ, White RI, Young LH, Zarrabeitia R: International Guidelines for the Diagnosis and Telangiectasia Management of Hereditary Hemorrhagic.

    J Med Genet 2011, 48:73-87. PubMed Abstract | Publisher Full Text OpenURL

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2377/11/84/prepub